Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2015

Net Loss per Share

Schedule of anti-dilutive securities

	Three months ended March 31,
(In thousands)	2015(1)	2014
Outstanding options and awards granted under equity incentive plan and ESPP	5,866	5,747
Unvested RSAs	1,930	2,193
Shares issuable upon conversion of convertible subordinated notes	12,494	10,347
	20,290	18,287

(1) Includes 4.5 million options, 0.6 million restricted stock units, and 1.2 million unvested restricted stock awards retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.